The Global Metabolomics Market in terms of revenue was estimated to be worth $1.9 billion in 2020 and is poised to reach $4.1 billion by 2025, growing at a CAGR of 13.4% from 2020 to 2025. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, availability of government and private funding for metabolomics research, and ongoing innovations in metabolomics instruments are driving the growth of the global metabolomics industry.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=900
Metabolomics Market Dynamics
Driver: Availability of government and private funding for metabolomics research
Metabolomic studies are gaining prominence in the life science industry as they help reveal the optimum level of specific metabolites associated with the onset/progression of a disease and the exposure or response to treatment. With the rising prevalence and mortality rate of life-threatening diseases, such as cancer and CVD, there is an increasing focus on novel approaches that can offer effective diagnosis and treatment of these diseases. As metabolomics is considered a novel approach with tremendous potential, additional research is being conducted in this field. Also, in recent years, the focus on metabolomic biomarkers has increased in drug development. As a result of these factors, government and private investments in metabolomics research is increasing.
Restraint: Issues related to data examination and processing
Metabolomics techniques produce a substantial volume of data as they create millions of data points per second over a 10-minute or more prolonged analysis. The continuous growth in the generation of high-volume heterogeneous data is increasing data complexity and it is becoming increasingly difficult to evaluate all these data points effectively. Moreover, due to the chemical diversity of small molecule metabolites, it is impossible to study the entire metabolome using a single analytical technique. As a result, the data produced is not only complex but also leads to a proportionate increase in the demand for physical storage, correct and rigorous analysis, and suitable software/databases for visualization. Thus, the high complexity of data generated during life science research and the difficulty in managing it is expected to hinder the growth of the market.
Opportunity: Biomarker development
Metabolomics is used to identify new biomarkers through bioinformatics tools, which indicate the changes in the physiological state of a cell or tissue. Biomarkers are important for developing in-vitro diagnostic tools, environmental toxicology screening methods, and drug discovery and development techniques. The omics revolution of the last decade has increased the application of metabolomics in biomedical research. As a result of these technological developments, new biomarkers are being regularly discovered. These biomarkers are required in medical sciences to better define and diagnose diseases, predict adverse drug events, and identify patient groups who would benefit from specific treatments. Moreover, in the near future, identifying biomarkers related to safety, sensitivity, and resistance to commercially available drugs will present significant growth opportunities for the market.
Request Free Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=900
By Product & Service, the separation tools accounted for the largest share of the metabolomics industry
The metabolomics instrument segment is expected to account for the largest market share in 2020. Factors such as the technological advancements in analytical instruments in terms of miniaturization, automation, and computerization; increase in the number of research-related activities worldwide in the field of medicine, nutraceuticals, and metabolomics; and strengthening healthcare infrastructure in developing nations for efficient disease diagnosis and treatment are expected to propel the growth of this segment during the forecast period
By Application, the biomarker discovery segment accounted for the largest share of the metabolomics industry
The biomarker discovery segment is expected to account for the largest market share in 2020. The use of metabolic biomarkers to assess the pathophysiological health status of patients is increasing. In recent years, as a result of significant technological advancements, metabolomics has become a vital tool in discovering biomarkers.
By Indication, Cancer segment expected to grow at the fastest growth rate during the forecast period.
Based on indication, the metabolomics market has been segmented into into cancer, cardiovascular disorders, neurological disorders, metabolic disorders, inborn errors of metabolism, and other indications (respiratory and infectious diseases. The cancer segment is expected to account for the largest market share in 2020, with the highest growth rate as well. This can primarily be attributed to the increasing number of patients who have cancer and the subsequent increase in the demand for cancer therapies.
By End User, Academic and Research Institutes accounted for the largest share of the metabolomics industry
The academic and research institutes segment accounted for the largest share of the global market in 2020. The increasing number of research activities in the field of metabolomics and funding to the academic and research institutes to conduct metabolomics research are the factors responsible for the largest share of the segment.
North America accounted for the largest share of the metabolomics industry in 2019
North America, which includes the US and Canada, accounted for the largest share of the global market. The large share of the North America region can be attributed to the presence of major players operating in the market in the US, growing biomedical research in the US, and rising preclinical activities by CROs and pharmaceutical companies in the region.
Key Market Players:
Waters Corporation (US), Agilent Technologies (US), Shimadzu Corporation (Japan), Thermo Fisher Scientific (US), Danaher Corporation (US), Bruker Corporation (US), PerkinElmer (US), Merck KGaA (Germany), GE Healthcare (US), Hitachi High-Technologies Corporation (Japan), Human Metabolome Technologies, Inc. (Japan), LECO Corporation (US), Metabolon, Inc. (US), Bio-Rad Laboratories (US), Scion Instruments (US), DANI Instruments S.p.A. (Italy), GL Sciences (Japan), SRI Instruments (US), Kore Technology Ltd. (UK), and JASCO, Inc. (US)
Recent Developments of Metabolomics Industry
- In 2020, Danaher Corporation acquired GE Healthcare’s Life Sciences business.
- In 2020, Agilent and Thermo Fisher extended their agreement to enhance the compatibility of Thermo Fisher’s analytical systems with Agilent’s OpenLAb Chromatography Data System
- In 2020, Waters Corporation announced the establishment of Immerse Cambridge, a research laboratory in the heart of Cambridge’s Kendall Square. Immerse Cambridge will serve as a strategic, collaborative space in the community, where Waters can partner with academia and research to accelerate the next generation of scientific advancements.
- In 2020, Hitachi acquired the remaining shares of Hitachi High-Technologies billion and made it its subsidiary. This subsidiary will be responsible for the manufacturing of measuring and analytical equipment, along with the development of chipmaking equipment and industrial materials and systems.
Inquiry Before Buying:
https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=900
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: 1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/metabolomics- technology.asp
Visit Our Web Site: https://www.marketsandmarkets.com
Content Source: https://www.marketsandmarkets.com/PressReleases/metabolomics-technology.asp
French (Français)
Spanish (Español)
Arabic
Portuguese (Português)
Deutsch
Turkish (Türk)
Dutch (Nederlands)
Italiano
Romaian (Română)
Português (Brasil)
Greek (Ελληνικά)
Russian (русский)